Linezolid Hetero

Linezolid Hetero Dosage/Direction for Use

linezolid

Manufacturer:

Hetero Labs

Distributor:

Medicell Pharma
Full Prescribing Info
Dosage/Direction for Use
Posology: Linezolid tablets 600mg solution for infusion, film-coated tablets or oral suspension may be used as initial therapy. Patients who commence treatment on the parenteral formulation may be switched to either oral presentation when clinically indicated. In such circumstances, no dose adjustment is required as linezolid has an oral bioavailability of approximately 100%.
Recommended dosage and duration of treatment for adults: Patients whose therapy is started with linezolid injection may be switched to linezolid tablets or linezolid for oral suspension, with no dosage adjustment. (See Table 2.)

Click on icon to see table/diagram/image

Paediatric population: Linezolid Hetero film coated tablets are not recommended for use in paediatrics.
Elderly: No dose adjustment is required.
Renal impairment: No dose adjustment is required (see Precautions and Pharmacology: Pharmacokinetics under Actions).
Severe renal impairment (i.e. CLCR < 30 ml/min): No dose adjustment is required. Due to the unknown clinical significance of higher exposure (up to 10 fold) to the two primary metabolites of linezolid in patients with severe renal insufficiency, linezolid should be used with special caution in these patients and only when the anticipated benefit is considered to outweigh the theoretical risk.
As approximately 30% of a linezolid dose is removed during 3 hours of haemodialysis, linezolid should be given after dialysis in patients receiving such treatment. The primary metabolites of linezolid are removed to some extent by haemodialysis, but the concentrations of these metabolites are still very considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency.
Therefore, linezolid should be used with special caution in patients with severe renal insufficiency who are undergoing dialysis and only when the anticipated benefit is considered to outweigh the theoretical risk.
To date, there is no experience of linezolid administration to patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or alternative treatments for renal failure (other than haemodialysis).
Hepatic impairment: No dose adjustment is required. However, there are limited clinical data and it is recommended that linezolid should be used in such patients only when the anticipated benefit is considered to outweigh the theoretical risk (see Precautions and Pharmacology: Pharmacokinetics under Actions).
Method of administration: The recommended linezolid dosage should be administered orally twice daily.
Route of administration: Oral use.
The film-coated tablets may be taken with or without food.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in